Table 3.
Significant results from subcortical structure analyses.
| Group comparisons | Hemisphere | Volume measure (mm3) | F | p | |
|---|---|---|---|---|---|
| VPA+ vs. VPA- | VPA+ | VPA- | |||
| Lateral ventricle | L | 7,162.71 | 5,436.5442 | 17 | 0.000 |
| R | 6,484.076 | 5,382.4883 | 12.2 | 0.001 | |
| VPA+ vs. Drug-naive | VPA+ | Drug-naive | |||
| Lateral ventricle | L | 7,162.71 | 4,857.9319 | 12 | 0.001 |
| R | 6,484.076 | 4,665.7277 | 12 | 0.001 | |
| VPA+ vs. HC | VPA+ | HC | |||
| Lateral ventricle | L | 7,162.71 | 5,241.2211 | 12 | 0.001 |
| R | 6,484.076 | 5,080.9842 | 12 | 0.001 | |
| Pallidum | R | 1,472.9045 | 1,551.3053 | 11.4 | 0.001 |
| Hippocampus | L | 4,188.306 | 4,585.5263 | 12.2 | 0.001 |
| VPA monotherapy vs. HC | VPA mono | HC | |||
| Lateral ventricle | L | 6,938.2818 | 5,241.2211 | 7 | 0.001 |
| R | 6,361.3636 | 5,080.9842 | 8 | 0.001 | |
| VPA monotherapy vs. Drug-naive | VPA mono | Drug-naive | |||
| Lateral ventricle | L | 6,938.2818 | 4,857.9319 | 6.4 | 0.001 |
| R | 6,361.3636 | 4,665.7277 | 6 | 0.001 | |
For each group comparison, only statistically significant measure (mm3) for each subgroup are included; F and p value are reported as results of statistical analysis.
VPA+, valproate users; VPA-, non-VPA users; HC, healthy controls; Mono, monotherapy.